Flush With CF Success, Vertex Prepares Next-Gen Pipeline For Busy 2023
Sickle Cell Therapy Could Be Approved Next Year
Executive Summary
Vertex’s dominance in cystic fibrosis looks secure for years to come, and 2023 and 2024 could see it bring more ground-breaking innovation to market.
You may also be interested in...
Vertex’s Non-Opioid Pain Candidate Hits Marks In Diabetic Peripheral Neuropathy
VX-548, which is set to read out Phase III data in acute pain in early 2024, demonstrated initial efficacy in chronic pain, but analysts say the drug will have to compete mainly on safety and tolerability.
Vertex/CRISPR Are First To US FDA With A CRISPR Gene-Editing Therapy For Sickle Cell Disease
The companies completed a rolling BLA filing for exagamglogene autotemcel (exa-cel) for sickle cell disease and beta thalassemia, a decade after the discovery of CRISPR.
Vertex Readies For Commercial Future For Multi-Therapeutic Area R&D Strategy
Chief operating officer Stuart Arbuckle and chief scientific officer David Altshuler talked to Scrip about potential launches in sickle cell disease and pain, and the firm’s expanding pipeline.